Mymetics Announces Change of Directors and Management

Tue Nov 27, 2012 6:33am EST

* Reuters is not responsible for the content in this press release.

  EPALINGES, SWITZERLAND, Nov 27 (MARKET WIRE) --
Mymetics Corporation (OTCBB:MYMX), a pioneer in the development of
vaccines that use the human mucosal system, the body's first line of
defense, to prevent transmission of infectious diseases, announced today
the appointment of Ronald Kempers, currently CFO and COO, as President
and CEO of Mymetics Corporation effective November 19, 2012. He replaces
Dr. Christopher S. Henney and Grant Pickering who had been respectively
appointed on March 22, 2012 as director and Chairman of the Board of
Directors and as a director and President and Chief Executive Officer to
pursue new strategic directions, including the potential change of
Mymetics' location from Switzerland to the United States.

    Mymetics will maintain its principal place of business in Switzerland as
it explores a number of strategic opportunities for its HIV, RSV and
other vaccine candidates under development. Mymetics will provide an
update in due time. 

    About Mymetics 

    Mymetics Corporation is a Swiss-based biotechnology company registered in
the US (OTCBB:MYMX) developing next-generation preventative vaccines for
infectious diseases. Mymetics' core technology and expertise are in the
use of virosomes, lipid-based carriers containing functional fusion viral
proteins with the ability to be combined with rationally designed
antigens. The company's vaccines are designed to induce protection
against early transmission and infection, focusing on the mucosal immune
response as a first-line defense, which for some pathogens may be
essential for the development of an effective prophylactic vaccine.
Mymetics currently has five vaccines in its pipeline: Respiratory
Syncytial Virus, Influenza, HIV-1/AIDS, Malaria and Herpes Simplex Virus.
The company's influenza, HIV-1 and malaria vaccines have completed Phase
I clinical trials in healthy human volunteers, while the RSV and HSV
vaccine candidates are in preclinical development. For further
information, please visit www.mymetics.com.

    Forward-looking statements 

    The Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for forward-looking statements, which are identified by the words
"believe," "expect," "anticipate," "intend," "plan" and similar
expressions. The statements contained herein which are not based on
historical facts are forward-looking statements that involve known and
unknown risks and uncertainties that could significantly affect our
actual results, performance or achievements in the future and,
accordingly, such actual results, performance or achievements may
materially differ from those expressed or implied in any forward-looking
statements made by or on our behalf. These risks and uncertainties
include, but are not limited to, risks associated with our ability to
successfully develop and protect our intellectual property, our ability
to raise additional capital to fund future operations and compliance with
applicable laws and changes in such laws and the administration of such
laws. See Mymetics' most recent Form 10-K for a discussion of such risks,
uncertainties and other factors. Readers are cautioned not to place undue
reliance on these forward-looking statements which speak only as of the
date the statements were made.

Contacts:
Mymetics Corporation
Ronald Kempers
President and CEO
+41 21 653 4884
www.mymetics.com

Media United States
Linnden Communications
Michelle Linn
508 362 3087
linnmich@comcast.net

Media Europe
Dynamics Group
Christophe Lamps
Senior Partner
+ 41 79 476 26 87
cla@dynamicsgroup.ch

Copyright 2012, Market Wire, All rights reserved.

-0-